Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer

Annals of Surgical Oncology

Volumn 17, Issue 9, 2010, Pages 2349-2356

  Yakabe, Tomomi ^a   Nakafusa, Yuji ^b   Sumi, Kenji ^a   Miyoshi, Atsushi ^a   Kitajima, Yoshihiko ^a   Sato, Seiji ^c   Noshiro, Hirokazu ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

^b FUKUOKA RED CROSS HOSPITAL   (Japan)

^c Saga Prefectural Hospital Koseikan   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; COLORECTAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77956338867     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1004-5     Document Type: Article

References (37)

1. JJ Tjandra MK Chan 2007 Follow-up after curative resection of colorectal cancer: a meta-analysis Dis Colon Rectum. 50 1783 1799 10.1007/s10350-007-9030-5 17874269
2. F Rodriguez-Moranta J Saló A Arcusa J Boadas V Piñol X Bessa, et al. 2006 Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial J Clin Oncol 24 386 393 10.1200/JCO.2005.02.0826 16365182
3. CE Desch AB Benson 3rd MR Somerfield PJ Flynn C Krause CL Loprinzi, et al. 2005 Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 23 8512 8519 10.1200/JCO.2005.04.0063 16260687
4. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.
5. C McArdle 2000 ABC of colorectal cancer: effectiveness of follow up BMJ 321 1332 1335 10.1136/bmj.321.7272.1332 1:STN:280:DC%2BD3M%2FmsVKjuw%3D%3D 11090519
6. B Ohlsson U Breland H Ekberg H Graffner KG Tranberg 1995 Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up Dis Colon Rectum 38 619 626 10.1007/BF02054122 1:STN:280: DyaK2M3pt1yhtQ%3D%3D 7774474
7. I Grossmann GH de Bock CJ van de Velde J Kievit T Wiggers 2007 Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice Colorectal Dis. 9 787 792 10.1111/j.1463-1318. 2007.01303.x 1:STN:280:DC%2BD2sngsF2itQ%3D%3D 17608748
8. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007:CD002200.
9. GB Secco R Fardelli D Gianquinto P Bonfante E Baldi G Ravera, et al. 2002 Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial Eur J Surg Oncol. 28 418 423 10.1053/ejso.2001.1250 12099653
10. GY Locker S Hamilton J Harris JM Jessup N Kemeny JS Macdonald, et al. 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol. 24 5313 5327 10.1200/JCO.2006.08.2644 1:CAS:528:DC%2BD28XhtlemurfN 17060676
11. MJ Duffy A van Dalen C Haglund L Hansson R Klapdor R Lamerz, et al. 2003 Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines Eur J Cancer. 39 718 727 10.1016/S0959-8049(02) 00811-0 1:CAS:528:DC%2BD3sXitVKgur8%3D 12651195
12. M Kouri S Pyrhonen P Kuusela 1992 Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma J Surg Oncol. 49 78 85 10.1002/jso.2930490204 1:STN:280:DyaK387kvFSrsQ%3D%3D 1738240
13. CC Chen SH Yang JK Lin TC Lin WS Chen JK Jiang, et al. 2005 Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 124 169 174 10.1016/j.jss.2004.08.013 1:CAS:528:DC%2BD2MXjtVyrsr4%3D 15820244
14. S Morita T Nomura Y Fukushima T Morimoto N Hiraoka N Shibata 2004 Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 47 227 232 10.1007/s10350-003-0041-6 15043294
15. N Eche MF Pichon V Quillien G Gory-Delabaere JM Riedinger JP Basuyau, et al. 2001 Standards, options and recommendations for tumor markers in colorectal cancer Bull Cancer. 88 1177 1206 1:STN:280:DC%2BD38%2FovFSqsg%3D%3D 11792611
16. P Barillari A Bolognese P Chirletti M Cardi P Sammartino V Stipa 1992 Role of CEA TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer Dis Colon Rectum. 35 471 476 10.1007/BF02049405 1:STN:280:DyaK383jtlOltw%3D%3D 1568399
17. T Ueda E Shimada T Urakawa 1994 The clinicopathologic features of serum CA 19-9-positive colorectal cancers Surg Today. 24 518 525 10.1007/BF01884571 1:STN:280:DyaK2M%2FgtlCgsg%3D%3D 7919734
18. JSCCR. Japanese Classification of Colorectal Carcinoma Second English Edition. Japanese Society for Cancer of the Colon and Rectum. 2009.
19. JA Hanley BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology. 143 29 36 1:STN:280: DyaL387ltFyksQ%3D%3D 7063747
20. CE Metz 1986 ROC methodology in radiologic imaging Invest Radiol. 21 720 733 10.1097/00004424-198609000-00009 1:STN:280:DyaL2s%2Fjt1Oqtw%3D%3D 3095258
21. JA Hanley BJ McNeil 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases Radiology. 148 839 843 1:STN:280:DyaL3s3nsVKgtg%3D%3D 6878708
22. I Chan W Wells 3rd RV Mulkern S Haker J Zhang KH Zou, et al. 2003 Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier Med Phys. 30 2390 2398 10.1118/1.1593633 14528961
23. MH Zweig G Campbell 1993 Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine Clin Chem. 39 561 577 1:CAS:528:DyaK3sXktVCitLs%3D 8472349
24. SG Baker 2003 The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer J Natl Cancer Inst. 95 511 515 10.1093/jnci/95.7.511 12671018
25. MG Shlipak LF Fried M Cushman TA Manolio D Peterson C Stehman-Breen, et al. 2005 Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors JAMA. 293 1737 1745 10.1001/jama.293.14.1737 1:CAS:528:DC%2BD2MXjtlWmtbo%3D 15827312
26. IA Gardner M Greiner 2006 Receiver-operating characteristic curves and likelihood ratios: improvements over traditional methods for the evaluation and application of veterinary clinical pathology tests Vet Clin Pathol. 35 8 17 10.1111/j.1939-165X.2006.tb00082.x 16511785
27. DL Simel GP Samsa DB Matchar 1991 Likelihood ratios with confidence: sample size estimation for diagnostic test studies J Clin Epidemiol. 44 763 770 10.1016/0895-4356(91)90128-V 1:STN:280:DyaK38%2FksVKrsw%3D%3D 1941027
28. BC Choi 1998 Slopes of a receiver operating characteristic curve and likelihood ratios for a diagnostic test Am J Epidemiol. 148 1127 1132 1:STN:280:DyaK1M%2FmsFerug%3D%3D 9850136
29. JE Fischer LM Bachmann R Jaeschke 2003 A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis Intensive Care Med. 29 1043 1051 10.1007/s00134-003-1761-8 12734652
30. MJ Pencina RB D'Agostino Sr RB D'Agostino Jr RS Vasan 2008 Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med. 27 157 172 10.1002/sim.2929 17569110 discussion 207-12
31. J Lokich S Ellenberg B Gerson WE Knox N Zamcheck 1984 Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy J Clin Oncol. 2 462 465 1:STN:280:DyaL2c3hsFahsQ%3D%3D 6374051
32. KS Goonetilleke AK Siriwardena 2007 Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol. 33 266 270 10.1016/j.ejso.2006.10.004 1:STN:280: DC%2BD2s7pvV2mtA%3D%3D 17097848
33. T Yoshimasu S Maebeya T Suzuma T Bessho H Tanino J Arimoto, et al. 1999 Disappearance curves for tumor markers after resection of intrathoracic malignancies Int J Biol Markers. 14 99 105 1:STN:280:DyaK1Mzislyhug%3D%3D 10399629
34. H Korner K Soreide PJ Stokkeland JA Soreide 2007 Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis Ann Surg Oncol. 14 417 423 10.1245/s10434-006-9060-6 17103264
35. IJ Park GS Choi KH Lim BM Kang SH Jun 2009 Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level Ann Surg Oncol. 16 3087 3093 10.1245/s10434-009-0625-z 19629600
36. T Nakayama M Watanabe T Teramoto M Kitajima 1997 CA19-9 as a predictor of recurrence in patients with colorectal cancer J Surg Oncol. 66 238 243 10.1002/(SICI)1096-9098(199712)66:4<238::AID-JSO3>3.0.CO;2-C 1:STN:280:DyaK1c%2Fos1CjtA%3D%3D 9425326
37. K Yamashita M Watanabe 2009 Clinical significance of tumor markers and an emerging perspective on colorectal cancer Cancer Sci. 100 195 199 10.1111/j.1349-7006.2008.01022.x 1:CAS:528:DC%2BD1MXhvVylsr0%3D 19200256